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Abstract Chronic pulmonary thromboembolic disease is an
important cause of severe pulmonary hypertension, and as
such is associated with significant morbidity and mortality.
The prognosis of this condition reflects the degree of associ-
ated right ventricular dysfunction, with predictable mortality
related to the severity of the underlying pulmonary hyperten-
sion. Left untreated, the prognosis is poor. Pulmonary endar-
terectomy is the treatment of choice to relieve pulmonary
artery obstruction in patients with chronic thromboembolic
pulmonary hypertension and has been remarkably successful.
Advances in surgical techniques along with the introduction
of pulmonary hypertension-specific medication provide ther-
apeutic options for the majority of patients afflicted with the
disease. However, a substantial number of patients are not
candidates for pulmonary endarterectomy due to either distal
pulmonary vascular obstruction or significant comorbidities.
Therefore, careful selection of surgical candidates in expert
centres is paramount. The current review focuses on the
diagnostic approach to chronic thromboembolic pulmonary
hypertension and the available surgical and medical therapeu-
tic options.
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Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH)
results from obstruction of the pulmonary vascular bed by
non-resolving thromboemboli [1]. Although anatomic resolu-
tion of acute embolism is often incomplete, sufficient resolu-
tion occurs in the majority of patients to restore normal pul-
monary haemodynamics associated with return to a pre-
embolism functional status [2]. Several prospective studies
have reported that between 0.6 and 4.6 % of acute pulmonary
embolic survivors will develop symptomatic CTEPH [3, 4].
However, previous reports have shown that 25–63 % of
patients with the established diagnosis of chronic thromboem-
bolic disease do not have previously documented acute ve-
nous thromboembolism [5–7].
CTEPH is defined by the following observations after at
least 3 months of effective anticoagulation: mean pulmonary
artery pressure (PAP) >25 mmHg with a pulmonary capillary
wedge pressure ≤ 5 mmHg; and perfusion defects detected by
appropriate imaging techniques [8].
The incidence of acute pulmonary embolism is approxi-
mately 1:1000 [9], and diagnosed in about 16,000 patients
annually in the Netherlands. The estimated cumulative inci-
dence of CTEPH in the Netherlands is 0.5–1.5 % [3].
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Historical data indicate that if left untreated CTEPH is
associated with a poor five-year survival, ranging from 10–
40 % depending on the pulmonary haemodynamics [10].
Pulmonary endarterectomy is the procedure of choice in
symptomatic patients with surgically accessible CTEPH [1].
After surgery, most patients experience a substantial haemo-
dynamic improvement, which is associated with improve-
ments in functional status and long-term survival [1, 11].
The 30-day mortality after pulmonary endarterectomy ranges
from less than 5 % in the most experienced centres to 10 % in
others [12, 13]. However, in 30–50 % of patients pulmonary
endarterectomy is not possible (inoperable CTEPH) due to
either distal pulmonary vascular obstruction or significant
comorbidities thought to be associated with unacceptably high
risk [14].
Furthermore, approximately 10–15 % of operated patients
suffer from persistent or recurrent pulmonary hypertension
[15]. When pulmonary endarterectomy is not possible or
when there is residual CTEPH after pulmonary endarterecto-
my, medical treatment with pulmonary hypertension-specific
medication may be an option. Therefore, careful selection of
the most appropriate treatment of CTEPH patients should be
done in specialised centres.
Pathophysiology and risk factors of CTEPH
Unlike pulmonary arterial hypertension (PAH), where vascu-
lar remodelling tends to occur in small pulmonary arteries,
CTEPH is associated with prominent obstructions in larger
vessels, combined with small vessel disease. The pathophys-
iology of CTEPH remains unclear. The embolic hypothesis
suggests that CTEPH is the result of single or recurrent pul-
monary embolism arising from sites of venous thrombosis
[16]. The European CTEPH Registry has recently revealed
that previous pulmonary embolism is detected in 74.8 % of all
CTEPH patients while previous deep venous thrombosis is
documented in 56.1 % of patients [17]. Recently, a prior
history of splenectomy, ventriculo-atrial shunt for the treat-
ment of hydrocephalus, thyroid replacement therapy, a history
of malignancy and chronic inflammatory disorders such as
osteomyelitis and inflammatory bowel disease, were associat-
ed with an increased risk of CTEPH [18]. Regarding details of
the acute embolic event, systolic PAP greater than 50 mmHg
at the time of diagnosis of acute embolism or at hospital
discharge, previous pulmonary embolism, and a larger degree
of pulmonary vascular obstruction at the time of acute pulmo-
nary embolism diagnosis have been identified as risk factors
for CTEPH [4, 19, 20].
According to current knowledge, CTEPH emerges as a
‘dual’ pulmonary vascular disorder with thrombosis inducing
major vessel vascular remodelling, combined with pulmonary
arteriopathy (small pulmonary vessel disease) as a
consequence of non-occluded area over-perfusion [5, 21,
22]. Lung biopsy findings obtained at the time of pulmonary
endarterectomy demonstrate pathohistological changes in the
microvasculature, similar to those seen in other forms of
small-vessel pulmonary hypertension, distal to both
obstructed and non-obstructed central arteries [21]. The
arteriopathy is considered to be the cause of the haemody-
namic and symptomatic decline over time by contributing to
the elevated pulmonary vascular resistance (PVR), thereby
adversely affecting cardiac function and eventually leading
to the progressive haemodynamic instability and increased
mortality observed in patients with CTEPH [10].
Endothelin-1 (ET-1) is a potent endogenous vasoconstric-
tor and is considered to contribute to the increase in vascular
tone and pulmonary vascular remodelling associated with
pulmonary hypertension [23]. It was demonstrated that endo-
thelial signalling pathway components are upregulated in
CTEPH [24]. Moreover, ET-1 levels were shown to signifi-
cantly decrease after successful pulmonary endarterectomy
[25]. These observations indicate that ET-1 may play a role
in the development of the secondary arteriopathy observed in
CTEPH. Therefore, ET-1 has been considered a potential
target for medical therapy in selected CTEPH patients [26].
Clinical manifestations and diagnostic work-up
Early in the course of the disease, the clinical presentation of
CTEPH can be subtle, which may contribute to the delay in
diagnosis (honeymoon period). The common symptom in
patients with CTEPH is exertional dyspnoea, the result of
increased dead space ventilation as well as a limitation in
cardiac output response to increased physiological demand
[27]. Progression of the disease and further limitation of
cardiac output may lead to signs of right heart failure,
exertion-related presyncope, and chest pain that may be due
to decreased right ventricular coronary flow related to in-
creased right ventricular systolic pressure and mass [28].
Physical examination findings early in the course of the
disease may be entirely unremarkable, thereby contributing to
diagnostic delay. As disease progression occurs, findings con-
sistent with pulmonary hypertension develop: prominence of
the right ventricular impulse, a closely split second heart
sound with accentuation of its pulmonary component, a right
ventricular S4 gallop, and varying degrees of tricuspid regur-
gitation. With the onset of right ventricular failure, jugular
venous distension, peripheral oedema, hepatomegaly, ascites,
a right-sided S3, and a widened split of the second heart sound
may be present.
Symptoms of disease are nonspecific and often attributed
to other cardio-respiratory disorders, deconditioning, or even
psychogenic disorders. Recent registry data showed a median
time interval of 14.1 months between the first symptoms and
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CTEPH diagnosis [17]. Indeed, CTEPH is associated with a
poor prognosis unless an early diagnosis is made and treat-
ment is started [10].
Once the possibility of a pulmonary vascular disease has
been considered, the diagnostic approach has three goals: first,
to establish the presence and extent of pulmonary hyperten-
sion, second to determine its cause, and third to evaluate the
therapeutic options.
Imaging studies are fundamental to decision-making with
respect to diagnosis and operability of CTEPH. However,
Klok et al. recently demonstrated that a simple diagnostic
model based on ECG evaluation and NT-pro-BNP measure-
ments was able to rule out CTEPH with a high level of
confidence in patients with a documented history of acute
and clinically suspected CTEPH [29].
Transthoracic echocardiography is sensitive for the detec-
tion of pulmonary hypertension and right ventricular dysfunc-
tion, but is not specific for the diagnosis of CTEPH. Common
echocardiographic findings include right ventricular hypertro-
phy, dilatation and impaired right ventricular systolic function.
Furthermore, right atrial enlargement, right ventricular pres-
sure overload and tricuspid regurgitation can be found (video
1). However, echocardiography is not able to distinguish acute
from sub-acute and chronic pulmonary embolism [30].
Stress echocardiography has been demonstrated to detect
pulmonary vascular disease prior to a rise of PAP at rest.
However, stress echocardiography needs further validation
and therefore is not recommended as a routine method [31].
Ventilation-perfusion lung scanning should always be per-
formed in the diagnostic work-up of pulmonary hypertension.
In patients with CTEPH, the ventilation-perfusion scan invari-
ably demonstrates one or more mismatched, segmental or
larger defects (Fig. 1) [32]. Normal findings on ventilation-
perfusion lung scanning rule out the diagnosis CTEPH and
other investigations should be performed to find the cause of
pulmonary hypertension [30]. Ventilation-perfusion lung
scanning does not anatomically localise the extent of disease
and cannot be used to determine surgical accessibility [30].
Computed tomography (CT) angiography may demon-
strate a variety of parenchymal, vascular, or mediastinal ab-
normalities in patients with CTEPH. These include a mosaic
parenchymal perfusion pattern, parenchymal scars, enlarge-
ment of the right ventricle and /or central pulmonary arteries,
asymmetry in the size and distribution of lobar and segmental
vessels, intraluminal thrombus, organised thrombus lining the
pulmonary vascular walls, arterial webs or bands, and medi-
astinal collateral vessels (Fig. 2a and b) [33]. Accuracy of CT
scanning has improved with technological advances, but a
negative CT scan does not rule out CTEPH [34].
Magnetic resonance imaging is a non-invasive technique
with no radiation exposure and offers great potential in
CTEPH diagnosis and risk stratification before pulmonary
endarterectomy [35]. It can be used for morphological,
anatomical and functional assessment of both the heart and
pulmonary circulation. Both high-resolution pulmonary angi-
ography and dynamic temporally resolved angiography can
be performed, with the latter enabling the detection of perfu-
sion defects (Fig. 3) [36].
Pulmonary angiography remains the gold standard. It es-
tablishes the diagnosis and assesses the operative resectability.
Specific angiographic patterns that correlate with operative
findings include pulmonary artery webs or bands, intimal
irregularities, abrupt stenosis or pouches of major pulmonary
arteries, and obstruction of lobar or segmental arteries at their
origins (Fig. 4) [37].
All patients with suspected CTEPH should be referred to
an experienced centre for confirmation of diagnosis and as-
sessment of operability.
Surgical treatment of CTEPH: pulmonary
endarterectomy
The treatment of choice for symptomatic patients with
CTEPH is pulmonary endarterectomy [1, 36, 38, 39]. The
principle and aim of the operation is the removal of obstruc-
tive material with an immediate reduction in PVR (Fig. 5).
The first successful true endarterectomy via sternotomy (with
cardiopulmonary bypass standby) was performed in 1962 by
Houk and colleagues [40]. Currently the pulmonary endarter-
ectomy procedure involves median sternotomy, cardiopulmo-
nary bypass and intermittent periods of hypothermic circula-
tory arrest to achieve a bloodless operative field and optimal
exposure of the pulmonary artery [41, 42]. Periods of circula-
tory arrest are limited to 20-minute intervals. In general, an
entire unilateral endarterectomy can usually be accomplished
within this time by an experienced surgeon. After each period
of circulatory arrest, reperfusion is carried out until at least
10 min has passed. The right pulmonary artery is incised
where it passes the aorta to the division of the lower lobe
arteries. On the left, the incision extends from the main pul-
monary artery to the origin of the left upper-lobe branch [38].
Pulmonary thrombo-endarterectomy bears no resemblance to
acute pulmonary embolectomy. The neo-intima in chronic
thromboembolic disease is not easily recognisable as chronic
thromboemboli and, thus, a true endarterectomy is necessary
to restore pulmonary arterial patency. An endarterectomy
plane is established between the intima and medial layer and
so removing the fibrotic thromboembolic material. Consider-
able surgical experience with this procedure is required to
identify the correct operative plane. A plane that is too deep
will result in perforation of the vessel, while a plane that is too
superficial will not result in an adequate endarterectomy.
Operability is based on the preoperative estimate of surgi-
cal classification [43] and the preoperative estimation of
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postoperative PVR, both of which determine risk of interven-
tion and probable outcome.
Outcome after pulmonary endarterectomy
Successful pulmonary endarterectomymarkedly improves the
haemodynamics, symptoms and functional status [12]. In the
majority of patients undergoing pulmonary endarterectomy,
both the short- and long-term haemodynamic outcomes are
favourable and may be regarded as permanent [38]. A dra-
matic and immediate postoperative reduction of the mean PAP
and PVR occurs. The mean reduction in PVR has approxi-
mated 70 % and a PVR in the range of 200 to 350 dyn·s·cm−5
can be achieved [15]. Patients in whom the postoperative PVR
decreases by at least 50 %, to a value of less than
500 dyn·sec·cm−5, have a more favourable prognosis after
surgery than those who do not: 30-day mortality rate of
1.2 % versus 5.7 % [41, 42]. The haemodynamic improve-
ment is associated with an improvement in the symptoms and
physical signs.
Overall 30-day mortality ranges from less than 5 % in the
most experienced centres to 10 % in others [12–14]. A mor-
tality rate of 1.3 % has been reported in patients at low risk
based on their preoperative haemodynamic profile [38]. Po-
tentially contributing to the improved outcome is a better
understanding of the natural history of the disease, earlier
and more selective surgical referral, improved diagnostic tech-
niques, and advances in postoperative care [2].
Patients undergoing pulmonary endarterectomy are subject
to many of the same postoperative complications as other
cardiothoracic surgical procedures, such as atelectasis, pleural
or pericardial effusion, diaphragmatic dysfunction and ar-
rhythmias. However, reperfusion oedema and residual or per-
sistent pulmonary hypertension are unique complications seen
Fig. 1 Lung perfusion scan in CTEPH, showing homogeneous ventilation and segmental defects in the perfusion scan
Fig. 2 a Contrast-enhanced chest
CT in CTEPH shows eccentric
thrombotic material within the left
pulmonary artery (arrow). b
Contrast-enhanced chest CT scan
in CTEPH before pulmonary
endarterectomy showing mosaic
perfusion
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in the pulmonary endarterectomy patient and are associated
with increased mortality [2].
Reperfusion oedema occurs in 10–40 % of patients, depend-
ing on the definition used. It is a high permeability oedema that
occurs in regions that have been endarterectomised and reper-
fused [44]. Reperfusion oedema is an early postoperative com-
plication with 60 % of cases presenting immediately after sur-
gery, 30 % developing within the first 48 h postoperatively and
the minority (10 %) occurring later during the hospitalisation
(>48 h) [39]. The severity of preoperative pulmonary hyperten-
sion and the presence of residual pulmonary hypertension are
associated with an increased risk of developing reperfusion
pulmonary oedema [45].
Mortality due to CTEPH is low among patients who sur-
vive 3 months post-endarterectomy. Reported five-year sur-
vival rates vary between 72 and 93 % [12–14].
Residual or persistent pulmonary hypertension after
pulmonary endarterectomy may result from incomplete
endarterectomy, inaccessible chronic thromboemboli or
small-vessel arteriopathy. The reported rates vary from
5 to 35 %, depending on the definition [46–48]. Al-
though it is associated with a higher risk of late post-
operative adverse events [12], functional improvement
might be achieved and the survival seems to be equiv-
alent to those patients without pulmonary hypertension
after pulmonary endarterectomy [46]. This may indicate
that the amount of PVR reduction matters, rather than
the final PVR [2].
Residual pulmonary hypertension and reperfusion
lung injury are often present in combination and, when
severe, conventional therapy has been proved ineffec-
tive. Extracorporeal membrane oxygenation can be help-
ful as a supportive measure for patients with severe
postendarterectomy complications and should be a stan-
dard of care in pulmonary endarterectomy centres [49].
Recently, clinical worsening has been used as a com-
posite endpoint in pulmonary arterial hypertension trials,
as described by McLaughlin [50]. It is a combination of
Fig. 3 Magnetic resonance
angiography in a patient with
CTEPH before (a) and after (b)
pulmonary endarterectomy
showing a normalisation of the
flow to the right lower lobe
(arrow). Reproduced (Eur Respir
Rev March 2012 21:32–39;
doi:10.1183/09059180.
00009211) with permission of the
publisher
Fig. 4 Pulmonary subtraction angiography of the right pulmonary artery
showing a subsegmental branch occlusion of anterior trunk of the right
upper lobe, an occlusion of the middle and lower lobe right pulmonary
artery
Fig. 5 The endarterectomy specimen showing a pouch in the right lower
lobe and the removal of fibrotic chronic thromboembolic material in the
distal sub-segmental branches
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mortality and different parameters which describe morbid-
ity after the initiation of specific therapy for pulmonary
hypertension. In recent reports, clinical worsening in
CTEPH patients was defined as the combination of death,
need for initiation of pulmonary hypertension-specific
medication after pulmonary endarterectomy or a 15 %
decrease in six-minute walking distance without improve-
ment in New York Heart Association (NYHA) functional
class. Clinical worsening has been described to occur in
20–30 % of the patients after pulmonary endarterectomy
[51, 52].
Predictors of outcome after pulmonary endarterectomy
After a haemodynamically successful pulmonary endar-
terectomy, the NYHA functional class improves and life
expectancy increases [11]. Possible preoperative predic-
tors for successful pulmonary endarterectomy are con-
sidered to be PVR, six-minute walking distance, radio-
logical findings and comorbidities of the patients [1, 7,
14]. Several studies have associated high preoperative
PVR (i.e. > 900–1100 dyn·s·cm−5) with increased mor-
tality after pulmonary endarterectomy [14, 38, 53]. The
postoperative PVR is also strongly related to mortality,
and a decrease to less than 500 dyn·s·cm−5 has been
reported as optimal [3]. Tscholl et al. demonstrated that
age, right atrial pressure, NYHA functional class, cardi-
ac output, creatinine and the number of angiographically
involved segments were significant predictors for early
death in univariate analysis. Age, right atrial pressure
and female gender were identified as risk factors for
unfavourable haemodynamic outcome after pulmonary
endarterectomy [54]. Bonderman and associates demon-
strated that the presence of associated medical condi-
tions (i.e. splenectomy, inflammatory bowel disease and
osteomyelitis) predicted increased operative risk and
worse long-term outcome in CTEPH (i.e. higher mortal-
ity rates and more frequent occurrence of residual pul-
monary hypertension) [47].
In a large prospective registry of Mayer et al., PVR three to
5 days after pulmonary endarterectomy and six-minute walk-
ing distance at diagnosis were identified as independent risk
factors for in-hospital death [14]. Survivors had a higher six-
minute walking distance and a lower PVR at diagnosis than
non-survivors. The one-year mortality rate increased with
increasing values of PVR at diagnosis to 12.8 % for those
with a PVR exceeding 1200 dyn·s·cm−5 [14].
A recent report by Schölzel et al. demonstrated that the
pulmonary artery diameter, indexed for body surface area,
was able to predict the occurrence of mortality within
30 days after pulmonary endarterectomy and for the oc-
currence of clinical worsening during follow-up in pa-
tients with operable CTEPH [52].
Medical treatment of chronic thromboembolic pulmonary
hypertension
All patients with CTEPH should receive lifelong
anticoagulation adjusted to a normalised target ratio between
2.0 and 3.0. The rationale is to prevent in situ pulmonary
artery thrombosis and recurrent venous thromboembolism.
Consideration about commencing medical therapy for
CTEPH patients should only occur following surgical assess-
ment, as the currently available drugs are not alternatives to
pulmonary endarterectomy [39].
Primary medical therapy and pretreatment with med-
ical therapy prior to pulmonary endarterectomy in pa-
tients who appear to have surgically accessible chronic
thromboembolic disease that seems proportionate with
the degree of pulmonary hypertension are currently not
recommended by the international guidelines. Patients
with ‘out of proportion’ elevated PVR prior to surgery,
persisting/residual pulmonary hypertension following
pulmonary endarterectomy (due to distal obstructive
thrombotic lesions situated beyond the sub-segmental
level but also due to arteriopathy), and inoperable
CTEPH are often considered for management with pul-
monary hypertension -targeted therapies, despite the fact
that these medications are not approved for the treat-
ment of CTEPH [26, 55].
A substantial number of patients (with operable and inop-
erable CTEPH) are currently being treated off-label. In the
International CTEPH Registry, 38 % of all patients were
treated with at least one drug targeting pulmonary hyperten-
sion at diagnosis [17].Most of the studies investigating the use
of pulmonary hypertension-targeted therapies in the manage-
ment of patients with distal CTEPH show beneficial effects
[56, 57]. The BENEFiTstudy is a large randomised controlled
trial that was performed in patients with inoperable CTEPH
(n=157) [26]. This study demonstrated a positive treatment
effect of bosentan (an endothelin receptor antagonist) on
haemodynamics in this patient population without improve-
ment of exercise capacity [26].
In the recent CHEST-1 study, the efficacy and side-effect
profile of riociguat (soluble guanylate cyclase stimulators)
was evaluated in patients with inoperable CTEPH and patients
with persistent or recurrent pulmonary hypertension after
pulmonary endarterectomy [58]. Riociguat significantly im-
proved exercise capacity and PVR in patients with CTEPH
compared with placebo [58].
Selected patients with a predicted higher risk for postoper-
ative mortality may benefit from preoperative medical treat-
ment, especially those in NYHA functional class IV, those
with a mean PAP greater than 50 mmHg, cardiac index less
than 2 L·min−1·m−2 and/or PVR greater than 1200 dyn·s·cm−5
or signs of right heart failure [57, 59]. Whether improving
pulmonary haemodynamics with preoperative pulmonary
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hypertension treatment also improves surgical outcome is
unknown and remains largely speculative [60]. In a ret-
rospective analysis of 9 patients who were treated with
continuous intravenous epoprostenol (a prostacyclin ana-
logue) before surgery, Bresser et al. found substantial
improvements in cardiac index, mean PAP and total
pulmonary resistance in all patients after pulmonary end-
arterectomy. However, impact on post-pulmonary endar-
terectomy morbidity and mortality could not be
established [59]. In a prospective randomised study by
Reesink et al., pulmonary haemodynamics and functional
capacity were analysed in 25 pulmonary endarterectomy
candidates treated with or without bosentan [61]. After
treatment of 16 weeks, significant improvements were
observed in mean PAP, total pulmonary resistance and
six-minute walking distance in the bosentan group com-
pared with controls. However, the outcome after pulmo-
nary endarterectomy was similar in both groups [61].
Jensen et al. retrospectively analysed the medical treat-
ment of the CTEPH patients referred to their centre for
pulmonary endarterectomy [62]. Although the use of pul-
monary hypertension-specific medication before surgery
had significantly increased, there was no significant im-
provement in preoperative pulmonary haemodynamics
and postoperative outcome [62].
The increased use of medications in operable patients
could possibly delay referral of patients for pulmonary
endarterectomy. Selection of suitable candidates for bridg-
ing therapy should be carefully carried out in expert
centres .
Conclusion
CTEPH has a poor prognosis if left untreated. Pulmo-
nary endarterectomy is the treatment of choice, offering
a potential cure. Peroperative mortality rates and post-
operative outcome have improved the last decades.
However, a substantial number of patients are not can-
didates for pulmonary endarterectomy due to either dis-
tal pulmonary vascular obstruction or significant comor-
bidities. Therefore, careful selection of surgical candi-
dates in expert centres is paramount.
New developments in medical treatment of inoperable
CTEPH and persistent or recurrent pulmonary hypertension
after pulmonary endarterectomy show promising results.
However, larger studies with mid- to long-term follow-up
are needed.
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